Cited by 29Treatment of Major DepressionEpigenetics and DNA MethylationGenetic Associations and Epidemiology

Epigenetic signatures in antidepressant treatment response: a methylome-wide association study in the EMC trial

Open access
Engelmann, J., Zillich, L., Frank, J., Wagner, S., Cetin, M., Herzog, D. P., Müller, M. B., Tadic, A. +12 more·2022·Translational Psychiatry

Published version of a preprint

Abstract

Although the currently available antidepressants are well established in the treatment of the major depressive disorder (MDD), there is strong variability in the response of individual patients. Reliable predictors to guide treatment decisions before or in an early stage of treatment are needed. DNA-methylation has been proven a useful biomarker in different clinical conditions, but its importance for mechanisms of antidepressant response has not yet been determined. 80 MDD patients were selected out of >500 participants from the Early Medication Change (EMC) cohort with available genetic material based on their antidepressant response after four weeks and stratified into clear responders and age- and sex-matched non-responders (N = 40, each). Early improvement after two weeks was analyzed as a secondary outcome. DNA-methylation was determined using the Illumina EPIC BeadChip. Epigenome-wide association studies were performed and differentially methylated regions (DMRs) identified using the comb-p algorithm. Enrichment was tested for hallmark gene-sets and in genome-wide association studies of depression and antidepressant response. No epigenome-wide significant differentially methylated positions were found for treatment response or early improvement. Twenty DMRs were associated with response; the strongest in an enhancer region in SORBS2, which has been related to cardiovascular diseases and type II diabetes. Another DMR was located in CYP2C18, a gene previously linked to antidepressant response. Results pointed towards differential methylation in genes associated with cardiac function, neuroticism, and depression. Linking differential methylation to antidepressant treatment response is an emerging topic and represents a step towards personalized medicine, potentially facilitating the prediction of patients' response before treatment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41398-022-02032-7

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Engelmann, J., Zillich, L., Frank, J., Wagner, S., Cetin, M., Herzog, D. P., Müller, M. B., Tadic, A., Foo, J. C., Sirignano, L., Braus, D. F., Dahmen, N., Sordon, S., Riemenschneider, M., Spaniol, C., Gasparoni, G., Rietschel, M., Witt, S. H., Lieb, K., & Streit, F.
Affiliations
  • University Medical Center of the Johannes Gutenberg University Mainz (DE)
  • Heidelberg University (DE)
  • Vitos (DE)
  • Universitätsklinikum des Saarlandes (DE)
  • Saarland University (DE)
Corresponding author
Streit, F.
Venue
Translational Psychiatry
Published
2022-07-07
Volume
12
Issue
1
Pages
268-268
ISSN
2158-3188 (ISSN-L)
OpenAlex
W4284891643
Cited by
29
References
63
Citations by year
2026: 9 · 2025: 8 · 2024: 8 · 2023: 4
FWCI
2.99
Type
journal article
Language
en
Open access
Locations
  • Translational Psychiatry (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Bundesministerium für Bildung und Forschung (01EW1904, 01 KG 0906)
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Keywords
antidepressant response, major depressive disorder, DNA methylation, differentially methylated regions, SORBS2, CYP2C18, early improvement, treatment response prediction, personalized medicine, enhancers
MeSH terms
Epigenome, Antidepressive Agents, Major Depressive Disorder, Depressive Disorder, Major, Diabetes Mellitus, Type 2, DNA, Humans, Epigenesis, Genetic, Genome-Wide Association Study

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review